06 Aug 2007 -
Dyax Corp. announced that they have licensed their antibody phage display libraries to Cambridge Antibody Technology (CAT), a wholly-owned subsidiary of AstraZeneca, for the discovery of therapeutic antibodies. CAT will receive sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology. The agreement allows CAT the ability to commercialize up to 20 royalty bearing therapeutic antibody products. Financial terms of the agreement are not disclosed.
Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, commented, "We are very pleased to have entered into an agreement with CAT, a company that has demonstrated the capability to discover, develop and commercialize therapeutic antibodies. This collaboration helps further validate Dyax's antibody phage display technology platform. We are continuing to create value in our Licensing and Funded Research Program, which has more than 70 collaborators and licensees, and has generated 13 product candidates that are currently in clinical trials."
Top
Contact
Print version
PDF version
Send article
RSS-Feed